Galderma Group N - Asset Resilience Ratio

Latest as of June 2025: 3.56%

Galderma Group N (GALD) has an Asset Resilience Ratio of 3.56% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Galderma Group N for a breakdown of total debt and financial obligations.

Liquid Assets

CHF458.00 Million

≈ $579.04 Million USD Cash + Short-term Investments

Total Assets

CHF12.88 Billion

≈ $16.28 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2024)

This chart shows how Galderma Group N's Asset Resilience Ratio has changed over time. See Galderma Group N book value and equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Galderma Group N's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Galderma Group N.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF458.00 Million	3.56%
Short-term Investments	CHF0.00	0%
Total Liquid Assets	CHF458.00 Million	3.56%

Asset Resilience Insights

Limited Liquidity: Galderma Group N maintains only 3.56% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Galderma Group N Industry Peers by Asset Resilience Ratio

Compare Galderma Group N's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Regencell Bioscience Holdings Ltd NASDAQ:RGC	Drug Manufacturers - Specialty & Generic	43.05%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	3.73%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.99%
Tonghua Dongbao Pharmaceutical Co Ltd SHG:600867	Drug Manufacturers - Specialty & Generic	1.96%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Guobang Pharma Ltd SHG:605507	Drug Manufacturers - Specialty & Generic	8.47%

Annual Asset Resilience Ratio for Galderma Group N (2021–2024)

The table below shows the annual Asset Resilience Ratio data for Galderma Group N.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.64%	CHF333.59 Million ≈ $421.75 Million	CHF12.62 Billion ≈ $15.95 Billion	+0.41pp
2023-12-31	2.23%	CHF234.26 Million ≈ $296.17 Million	CHF10.49 Billion ≈ $13.26 Billion	+2.23pp
2022-12-31	0.00%	CHF185.04K ≈ $233.94K	CHF11.49 Billion ≈ $14.52 Billion	-0.02pp
2021-12-31	0.02%	CHF2.46 Million ≈ $3.11 Million	CHF11.45 Billion ≈ $14.48 Billion	--

pp = percentage points

About Galderma Group N

SW:GALD Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$48.63 Billion

CHF38.46 Billion CHF

Market Cap Rank

#719 Global

#11 in Switzerland

Share Price

CHF163.80

Change (1 day)

+2.89%

52-Week Range

CHF97.10 - CHF167.80

All Time High

CHF167.80